Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862
View directory record Official record
Conditions
Common Warts
Interventions
A-101 Solution 40, A-101 Solution 45, Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196
View directory record Official record
Conditions
Alopecia Areata (AA)
Interventions
ALD-102 Solution, Placebo or Control
Drug · Other
Lead sponsor
Aldena Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo, Acetaminophen
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597
View directory record Official record
Conditions
Dry Eye Disease
Interventions
A197 Ophthalmic Solution, A197 Vehicle Control, Active Comparator
Drug
Lead sponsor
Aramis Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

NCT06840496
View directory record Official record
Conditions
Rett Syndrome
Interventions
Bionetide, Placebo
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
5 Years to 20 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT06136741
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Bryant, Arkansas • Fountain Valley, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Results available

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study

NCT03340805
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT05896670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
licaminlimab, vehicle of OCS-02, Artificial tears
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Newport Beach, California • Colorado Springs, Colorado • Shelby, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Grape Impact on Human Gut Microbiome

NCT07797803
View directory record Official record
Conditions
Gut Microbiomes
Interventions
Grape Powder, Placebo Powder
Dietary Supplement · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings

NCT05074524
View directory record Official record
Conditions
Opioid-use Disorder, Heroin Abuse, Craving, Transcranial Magnetic Stimulation
Interventions
Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 2Phase 3 Interventional

Tranexamic Acid to Reduce Blood Loss in Spine Surgery

NCT02314988
View directory record Official record
Conditions
Spinal Injuries, Spinal Deformity
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
San Francisco, California • Louisville, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

NCT02620761
View directory record Official record
Conditions
Patent Ductus Arteriosus (PDA), Acute Kidney Injury (AKI)
Interventions
Fenoldopam, 0.9%NS
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
0 Days to 28 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

NCT06164743
View directory record Official record
Conditions
Inflammation
Interventions
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Inglewood, California • Petaluma, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systemic Steroids for Peripheral Nerve Blocks

NCT02464176
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Dexamethasone, Bupivacaine, Epinephrine, Lumbar Plexus Nerve Block, Saline
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

NCT06067438
View directory record Official record
Conditions
Atrial Fibrillation, Esophageal Carcinoma
Interventions
Amiodarone Hydrochloride, Saline
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT01121185
View directory record Official record
Conditions
HCV Infection, Liver Transplantation
Interventions
MBL-HCV1, 0.9% Sodium chloride Placebo
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

End-stage Renal Disease (ESRD) Pilot Study

NCT03787368
View directory record Official record
Conditions
Renal Dialysis
Interventions
BAY1213790, 0.9% sodium chloride solution
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414
View directory record Official record
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 5:32 AM EDT